National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dabrafenib plus Trametinib (Tafinlar® plus Mekinist®)

Dabrafenib, in combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

NCPE Assessment Process Complete
Rapid Review commissioned 30/01/2019
Rapid Review completed 21/03/2019
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dabrafenib plus trametinib (Tafinlar® plus Mekinist®) compared with the current standard of care.

 

Full pharmacoeconomic assessment commissioned by HSE 09/04/2019
Pre-submission consultation with Applicant 28/05/2019
Submission received from Applicant 02/09/2019
Preliminary review sent to Applicant 09/04/2020
NCPE assessment re-commenced 18/05/2020
Factual accuracy check sent to Applicant 10/07/2020
NCPE assessment re-commenced 20/07/2020
NCPE assessment completed 19/08/2020
NCPE assessment outcome The NCPE recommend that dabrafenib and trametinib be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.